SCHEMBL3946646

SCHEMBL3946646

COc1cccc(OCCN2CCOCC2)c1-c1ccnc(N)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.50
TSHR P16473 1/20 0.50
ADCY10 Q96PN6 2/20 0.47
HSP90AA1 P07900 1/20 0.45
HSP90AB1 P08238 1/20 0.45
SYK P43405 1/20 0.45
KDM4E B2RXH2 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
ALDH1A1 P00352 2/20 0.44
HTR2C P28335 1/20 0.44
HTR2B P41595 1/20 0.44
MAPK13 O15264 1/20 0.44
MAPK12 P53778 1/20 0.44
MAPK11 Q15759 1/20 0.44
MAPK14 Q16539 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
RAB9A P51151 1/20 0.44
PTPN1 P18031 1/20 0.43
PDPK1 O15530 1/20 0.43
DRD1 P21728 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3951667 0.85 ADCY10 (0.63) CYP2D6TSHRADCY10HSP90AA1HSP90AB1
SCHEMBL3664825 0.76 KMO (0.57) TSHRADCY10HSP90AA1HSP90AB1MAPK13
SCHEMBL7786453 0.75 CYP2D6 (0.56) CYP2D6TSHRSYKKDM4ETDP1
SCHEMBL5319656 0.75 KDM4E (0.70) CYP2D6TSHRSYKKDM4ETDP1
SCHEMBL13744516 0.74 SMN1; SMN2 (0.66) CYP2D6TSHRSYKKDM4ETDP1
SCHEMBL4221151 0.74 HSP90AA1 (0.65) TSHRADCY10HSP90AA1HSP90AB1HTR2C
Ammonia Solution, Strong SCHEMBL4267670 0.74 KDM4E (0.68) CYP2D6TSHRSYKKDM4ETDP1
SCHEMBL11927962 0.73 MTOR (0.65) CYP2D6TSHRKDM4ETDP1
SCHEMBL2011534 0.73 CYP2D6 (0.60) CYP2D6TSHRSYKKDM4ETDP1
SCHEMBL7792380 0.73 CYP2D6 (0.53) CYP2D6TSHRSYKKDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 US disclosed
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 US disclosed
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 US disclosed
EP-2049497-A2 PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS Astex Therapeutics Limited (GB) 2009-04-22 EP disclosed
WO-2006123165-A2 PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors HSP90AB1, HSP90AB2P, HSP90B1 CYP2D6 1723/4885TSHR 2843/4885ADCY10 3897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.